恩華藥業(002262.SZ):參股子公司江蘇好欣晴獲增資1.25億元
格隆匯5月7日丨恩華藥業(002262.SZ)公佈,公司的參股子公司江蘇好欣晴為了加快業務發展,進一步調整和優化股權架構,提升經營管理水平,擬引入新股東增加資本金。公司同意江蘇好欣晴此次增資方案並放棄優先認繳出資權。
江蘇好欣晴此次融資1.25億元,其中:新增註冊資本約2379.46萬元,其餘約1.01億元計入資本公積金。此次融資分別由通和毓承、華創、景得共同出資進行認購,此次融資、增資完成後,公司對江蘇好欣晴的出資比例將由38.2739%降至28.2018%,江蘇好欣晴仍為公司的參股子公司。
作為目前國內最大的服務於中樞神經類疾病互聯網醫療平台和智能化慢病管理平台之一,截止2020年2月底,江蘇好欣晴(好心情)平台註冊精神心理科和神經科等科室已認證醫生超過2.7萬名,其中精神心理科醫生註冊總數佔國內總數70%以上,註冊用户超過300萬人,每月服務患者人次超過10萬人次,是國內移動醫療平台的一支新秀。
公司表示,江蘇好欣晴(好心情)作為公司重點培育孵化的創新性企業,此次公司放棄對江蘇好欣晴增資優先認繳權,由通和毓承、華創(中華開發)、景得(KIP)進行增資認購,一方面優化了江蘇好欣晴股權結構,另一方面滿足了江蘇好欣晴發展的資金需求,引進了通和毓成等三家國內外頂級投資機構,有利於江蘇好欣晴引進高端人才,加快推進江蘇好欣晴上市進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.